MX3042E - Procedimiento para preparar derivados de quinoxalina o - quinazolina de 2 - imidazolin - 2 ilaminas - Google Patents

Procedimiento para preparar derivados de quinoxalina o - quinazolina de 2 - imidazolin - 2 ilaminas

Info

Publication number
MX3042E
MX3042E MX129473U MX129473U MX3042E MX 3042 E MX3042 E MX 3042E MX 129473 U MX129473 U MX 129473U MX 129473 U MX129473 U MX 129473U MX 3042 E MX3042 E MX 3042E
Authority
MX
Mexico
Prior art keywords
ilamines
imidazolin
procedure
quinazoline derivatives
quinoxaline
Prior art date
Application number
MX129473U
Other languages
English (en)
Inventor
John Christopher Danilevick
Michael Snarey
Geoffrey Noel Thomas
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX3042E publication Critical patent/MX3042E/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX129473U 1972-02-29 1973-02-15 Procedimiento para preparar derivados de quinoxalina o - quinazolina de 2 - imidazolin - 2 ilaminas MX3042E (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919672A GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline
GB5162972 1972-11-08

Publications (1)

Publication Number Publication Date
MX3042E true MX3042E (es) 1980-03-04

Family

ID=26242776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX129473U MX3042E (es) 1972-02-29 1973-02-15 Procedimiento para preparar derivados de quinoxalina o - quinazolina de 2 - imidazolin - 2 ilaminas

Country Status (16)

Country Link
US (1) US3890319A (es)
JP (2) JPS5754516B2 (es)
AR (1) AR213705A1 (es)
AU (1) AU471598B2 (es)
BE (1) BE795970A (es)
CA (1) CA981678A (es)
CH (2) CH576975A5 (es)
DE (1) DE2309160A1 (es)
ES (2) ES411804A1 (es)
FI (1) FI63757C (es)
FR (1) FR2181776B1 (es)
GB (1) GB1381979A (es)
IE (1) IE37519B1 (es)
MX (1) MX3042E (es)
NL (1) NL159102B (es)
SE (1) SE417204B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
JPS542338A (en) 1977-04-22 1979-01-09 Sandoz Ag Pharmaceutical composition
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
US4486432A (en) * 1982-09-30 1984-12-04 Eli Lilly And Company Quinoxalinedione leukotriene release inhibitors
FR2541680B1 (fr) * 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
JPS6118950U (ja) * 1984-07-10 1986-02-03 財団法人鉄道総合技術研究所 トロリ線の給油装置
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
CA2173974C (en) * 1993-10-13 2006-05-02 James A. Burke Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
SG44628A1 (en) * 1993-12-17 1997-12-19 Procter & Gamble 6-(2-imidazolinylamino) Quinoxaline compounds useful as alpha-2 adrenoceptor agonists
PT736020E (pt) * 1993-12-17 2000-10-31 Procter & Gamble Compostos 6-(2-imidazolinilamino)quinolina uteis como alfa-2 adrenoceptor agonistas
WO1995021818A1 (en) * 1994-02-08 1995-08-17 Alcon Laboratories, Inc. Novel process for preparation of clonidine derivatives
EP0775134A4 (en) * 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) * 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
AU5433898A (en) * 1996-11-25 1998-06-22 Procter & Gamble Company, The 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
CN1092652C (zh) * 1996-11-25 2002-10-16 普罗克特和甘保尔公司 2－咪唑啉基氨基吲哚化合物及含有它的组合物和应用
HUP0000312A3 (en) 1996-11-25 2001-12-28 Procter And Gamble Co Cincinna Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists and pharmaceutical compositions containing them
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
ID22060A (id) * 1996-11-25 1999-08-26 Procter & Gamble Senyawa-senyawa 2-imidazolinilaminobenzoksazol berguna sebagai agonis adrenoseptor
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
BR9815017A (pt) 1997-11-24 2001-09-11 Procter & Gamble Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
HU230383B1 (hu) * 2000-07-14 2016-03-29 Allergan, Inc Oldékonyságfokozó komponens használata brimodinin-tartarátot tartalmazó vizes készítményekben
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
WO2004032913A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
CN100370988C (zh) * 2002-10-08 2008-02-27 阿勒根公司 (2-咪唑啉-2-基氨基)喹噁啉在制备治疗痴呆症和帕金森病的药物中的用途
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
KR101028952B1 (ko) * 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
DK1761266T3 (da) 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
AU2010303545B2 (en) 2009-10-06 2016-05-12 Allergan, Inc. 2H-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
JP5747392B2 (ja) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
AU2011231543B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
WO2011127151A2 (en) 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
CA2796041A1 (en) 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
TR201818754T4 (tr) 2010-07-29 2019-01-21 Allergan Inc Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
DK2444068T4 (en) 2010-10-21 2018-03-05 Galderma Sa Brimonide sub-composition
EP2736902A1 (en) * 2011-07-25 2014-06-04 Allergan, Inc. N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.

Also Published As

Publication number Publication date
ES411804A1 (es) 1976-05-01
FI63757B (fi) 1983-04-29
AU471598B2 (en) 1976-04-29
CA981678A (en) 1976-01-13
FI63757C (fi) 1983-08-10
AU5198573A (en) 1974-08-08
JPS5625176A (en) 1981-03-10
IE37519L (en) 1973-08-29
ES412102A1 (es) 1976-05-16
DE2309160A1 (de) 1973-09-27
NL7302799A (es) 1973-08-31
BE795970A (fr) 1973-08-27
CH577500A5 (es) 1976-07-15
IE37519B1 (en) 1977-08-17
GB1381979A (en) 1975-01-29
JPS5745439B2 (es) 1982-09-28
JPS4897878A (es) 1973-12-13
AR213705A1 (es) 1979-03-15
FR2181776A1 (es) 1973-12-07
SE417204B (sv) 1981-03-02
US3890319A (en) 1975-06-17
CH576975A5 (es) 1976-06-30
FR2181776B1 (es) 1976-08-13
NL159102B (nl) 1979-01-15
JPS5754516B2 (es) 1982-11-18

Similar Documents

Publication Publication Date Title
MX3042E (es) Procedimiento para preparar derivados de quinoxalina o - quinazolina de 2 - imidazolin - 2 ilaminas
AR214612A1 (es) Procedimiento para preparar nuevos derivados de 1-piridiloxi-,1-piraziniloxi-,1-pirodaziniloxi o 1-pirimidiniloxi-2-hidroxi-3-amino-propano
AR195412A1 (es) Procedimiento para la preparacion de derivados de 4-difenilmetil- y 4-difenilmetilenpiperidino
AR203373A1 (es) Procedimiento para preparar 4-amino-quinazolinas
AR212028A1 (es) Procedimiento para obtener derivados de 7beta-amino-3-cefemol-4-carboxilicos
AR205611A1 (es) Procedimiento para la preparacion de derivados de 3-fenoxi-2-hidroxi-propilamina
AR204982A1 (es) Procedimiento para preparar nuevos derivados de 1-fenoxi-2hidroxi-3-isopropilamina
AR199672A1 (es) Procedimiento para producir compuestos heterociclicos
AR219038A1 (es) Procedimiento para la preparacion de derivados de 1-hidroxi-2-piridonas-6-substituidas
AR207946A1 (es) Procedimiento para preparar 2-amino-metilenindanona
AR200500A1 (es) Procedimiento para la obtencion de nuevos derivados de diazapina
AR200869A1 (es) Procedimiento para la obtencion de nuevos derivados del 1-fenoxi-3-amino-propan-2-ol
AR206505A1 (es) Procedimiento para obtener nuevos derivados de n-fenil-n-aminoalquil-2-aminoindano
AR206887A1 (es) Procedimiento para preparar nuevos d-2-halo-6-metil-8-cianometilergolinas
AR200736A1 (es) Procedimiento para producir nuevos compuestos de piperacinil quinazolinadionas
AR207744A1 (es) Procedimiento para la preparacion de nuevos derivados de isotiocianopiridinas
AR203090A1 (es) Procedimiento para la preparacion de derivados de hexahidro-pirimidino-dibenzo-azepina
AR207554A1 (es) Procedimiento para producir derivados de 3-alquil-5-((3,4-dihidro-5-carbostiril)oximetil)-oxazolidinona-(2)
AR202283A1 (es) Procedimiento para la preparacion de derivados de 1-piperidinsulfonilurea
AR195913A1 (es) Procedimiento para la produccion de derivados 6-piperazinilicos de morfantridina y de analogos heterociclicos de la misma
AR205437A1 (es) Procedimiento para la preparacion de derivados de indoloquinolinona
AR201427A1 (es) Procedimiento para la preparacion de derivados de cefalosprina
AR197057A1 (es) Procedimiento para preparar 1- arilidenamino-4- (2 - oxo -3 - fenil - 3 - benzofuril) piperacinas
AR207633Q (es) Procedimiento para la elaboracion de nuevos derivados de 2-benzoil-3-amino-6-cloro-piridinas
AR200576A1 (es) Procedimiento para la preparacion de derivados pirazolicos